Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors

European Journal of Surgical Oncology

Volumn 34, Issue 5, 2008, Pages 563-568

  Tzen, C Y ^a,b,c,d   Wang, M N ^a   Mau, B L ^e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e Sun Yat Sen Cancer Center   (Taiwan)

Author keywords

GIST; KIT gene; Mutation; Prognosis; Targeted therapy

Indexed keywords

IMATINIB;

ADULT; ARTICLE; CANCER SURVIVAL; CHI SQUARE TEST; CLINICAL FEATURE; CODON; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE DELETION; GENE INSERTION; GENE MUTATION; HUMAN; KIT GENE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MITOSIS RATE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PDGFRA GENE; PRIORITY JOURNAL; PROGNOSIS; TAIWAN;

FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TAIWAN;

EID: 41949121434     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.04.005     Document Type: Article

References (28)

1. Kindblom L.G., Remotti H.E., Aldenborg F., and Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of cajal. Am J Pathol 152 (1998) 1259-1269
2. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
3. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156 (2000) 791-795
4. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
5. Heinrich M.C., Rubin B.P., Longley B.J., and Fletcher J.A. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33 (2002) 484-495
6. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
7. Antonescu C.R., Sommer G., Sarran L., et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9 (2003) 3329-3337
8. Lasota J., Kopczynski J., Sarlomo-Rikala M., et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 34 (2003) 1306-1312
9. Miettinen M., Makhlouf H., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30 (2006) 477-489
10. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106 (2003) 887-895
11. Martín J., Poveda A., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish group for sarcoma research (GEIS). J Clin Oncol 23 (2005) 6190-6198
12. Penzel R., Aulmann S., Moock M., Schwarzbach M., Rieker R.J., and Mechtersheimer G. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 58 (2005) 634-639
13. Tzen C.Y., Wang J.H., Huang Y.J., et al. Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses. Dig Dis Sci 52 (2007) 792-797
14. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 (2002) 459-465
15. Tzen C.Y., Huang Y.W., and Fu Y.S. Is atypical follicular adenoma of the thyroid a preinvasive malignancy?. Hum Pathol 34 (2003) 666-669
16. Tzen C.Y., and Mau B.L. Analysis of CD117-negative gastrointestinal stromal tumors. World J Gastroenterol 11 (2005) 1052-1055
17. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
18. Agaram N.P., Baren A., Arkun K., Dematteo R.P., Besmer P., and Antonescu C.R. Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors. Ultrastruct Pathol 30 (2006) 443-452
19. He H.Y., Fang W.G., Zhong H.H., et al. Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST). Zhonghua Bing Li Xue Za Zhi 35 (2006) 262-266
20. Andersson J., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130 (2006) 1573-1581
21. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29 (2005) 52-68
22. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61 (2001) 8118-8121
23. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 (2005) 5357-5364
24. Yeh C.N., Chen T.W., Lee H.L., et al. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from chang gung memorial hospital. Ann Surg Oncol 14 (2007) 1123-1128
25. Chou T.Y., Chiu C.H., Li L.H., et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 3750-3757
26. Hsieh R.K., Lim K.H., Kuo H.T., Tzen C.Y., and Huang M.J. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128 (2005) 317-321
27. Sakurai S., Fukasawa T., Chong J.M., Tanaka A., and Fukayama M. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of cajal). Jpn J Cancer Res 90 (1999) 1321-1328
28. Koay M.H., Goh Y.W., Iacopetta B., et al. Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases. Pathology 37 (2005) 22-31